[{"id":14170,"run_id":444,"as_of":"2026-09-16","ticker":"NAMS","company":"Newamsterdam Pharma Co N.V.","source":"weekly","conviction":24.7,"technical":30.9,"stage":"No Long Regime","gated":true,"n_gates":4,"gates":["Price below the 200DMA — no long regime.","200DMA is not rising — regime not clear.","50DMA is not rising.","Insiders are net sellers — net purchase ratio -0.96 over the last 180 days (3 selling vs 1 buying). Other insiders bought (1 CEO), but the group remains net sellers; there is no CFO purchase to offset the selling."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":21.18,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":2.8,"Volatility behaviour":5.5,"Cross-asset confirmation":9.4,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":0.0},"total_cfo_value":0.0,"total_other_value":226500.0,"n_cfo_buys":0.0,"n_other_buys":1.0,"has_cfo_buy":false,"roles_buying":"1 CEO","npr":-0.9562083042395678,"cluster_insiders":1.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-16T21:30:15.198638+00:00"},{"id":14764,"run_id":451,"as_of":"2026-09-17","ticker":"NAMS","company":"Newamsterdam Pharma Co N.V.","source":"weekly","conviction":24.4,"technical":30.5,"stage":"No Long Regime","gated":true,"n_gates":4,"gates":["Price below the 200DMA — no long regime.","200DMA is not rising — regime not clear.","50DMA is not rising.","Insiders are net sellers — net purchase ratio -0.96 over the last 180 days (3 selling vs 1 buying). Other insiders bought (1 CEO), but the group remains net sellers; there is no CFO purchase to offset the selling."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":21.93,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":2.7,"Volatility behaviour":5.5,"Cross-asset confirmation":9.2,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":0.0},"total_cfo_value":0.0,"total_other_value":226500.0,"n_cfo_buys":0.0,"n_other_buys":1.0,"has_cfo_buy":false,"roles_buying":"1 CEO","npr":-0.9562083042395678,"cluster_insiders":1.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-17T21:06:22.295534+00:00"},{"id":15373,"run_id":455,"as_of":"2026-10-14","ticker":"NAMS","company":"Newamsterdam Pharma Co N.V.","source":"weekly","conviction":29.8,"technical":37.2,"stage":"No Long Regime","gated":true,"n_gates":4,"gates":["Price below the 200DMA — no long regime.","200DMA is not rising — regime not clear.","50DMA is not rising.","Insiders are net sellers — net purchase ratio -0.96 over the last 180 days (3 selling vs 1 buying). Other insiders bought (1 CEO), but the group remains net sellers; there is no CFO purchase to offset the selling."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":20.01,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":3.0,"Volatility behaviour":9.5,"Cross-asset confirmation":0.0,"Sponsorship / positioning":17.3,"Catalyst alignment (insider)":0.0},"total_cfo_value":0.0,"total_other_value":226500.0,"n_cfo_buys":0.0,"n_other_buys":1.0,"has_cfo_buy":false,"roles_buying":"1 CEO","npr":-0.9609552904460957,"cluster_insiders":1.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-10-14T21:57:05.171892+00:00"},{"id":15457,"run_id":456,"as_of":"2026-10-15","ticker":"NAMS","company":"Newamsterdam Pharma Co N.V.","source":"weekly","conviction":43.6,"technical":54.5,"stage":"No Long Regime","gated":true,"n_gates":4,"gates":["Price below the 200DMA — no long regime.","200DMA is not rising — regime not clear.","50DMA is not rising.","Insiders are net sellers — net purchase ratio -0.96 over the last 180 days (3 selling vs 1 buying). Other insiders bought (1 CEO), but the group remains net sellers; there is no CFO purchase to offset the selling."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":20.62,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":3.0,"Volatility behaviour":9.5,"Cross-asset confirmation":14.0,"Sponsorship / positioning":17.1,"Catalyst alignment (insider)":0.0},"total_cfo_value":0.0,"total_other_value":226500.0,"n_cfo_buys":0.0,"n_other_buys":1.0,"has_cfo_buy":false,"roles_buying":"1 CEO","npr":-0.9609552904460957,"cluster_insiders":1.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-10-15T21:13:44.615367+00:00"},{"id":16048,"run_id":458,"as_of":"2026-10-16","ticker":"NAMS","company":"Newamsterdam Pharma Co N.V.","source":"weekly","conviction":43.3,"technical":54.1,"stage":"No Long Regime","gated":true,"n_gates":4,"gates":["Price below the 200DMA — no long regime.","200DMA is not rising — regime not clear.","50DMA is not rising.","Insiders are net sellers — net purchase ratio -0.96 over the last 180 days (3 selling vs 1 buying). Other insiders bought (1 CEO), but the group remains net sellers; there is no CFO purchase to offset the selling."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":19.83,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":3.0,"Volatility behaviour":9.5,"Cross-asset confirmation":14.0,"Sponsorship / positioning":16.8,"Catalyst alignment (insider)":0.0},"total_cfo_value":0.0,"total_other_value":226500.0,"n_cfo_buys":0.0,"n_other_buys":1.0,"has_cfo_buy":false,"roles_buying":"1 CEO","npr":-0.9609552904460957,"cluster_insiders":1.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-10-16T20:55:56.165619+00:00"}]